What drugs does VIVUS INC make?

VIVUS INC has 3 FDA-approved drugs including QSYMIA, STENDRA.

What therapeutic areas does VIVUS INC focus on?

VIVUS INC focuses primarily on Metabolic and Oncology.

← Back

Data updated: Mar 29, 2026

VIVUS INC

MetabolicOncology

Biotech

VIVUS INC is a biotechnology company focused on Metabolic, Oncology. Key products include QSYMIA.

2010

Since

Drugs

Trials

Approved (2yr)

Key Drugs

QSYMIA

phentermine hydrochloride

Metabolic

AMPA receptor 2 indications · 2012

STENDRA

avanafil

PDE5 1 indications · 2012

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Recent Activity

SEC Filings ProEarly access

Therapeutic Areas

Score weights: Approved drugs ×3, Phase 3 ×2, Phase 2 ×1, Phase 1 ×0.5

Metabolic 80%

1 drugs Phase 1: 2

Oncology 20%

0 drugs Phase 2: 1

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

Merck big-pharma

Oncology, Metabolic

Johnson & Johnson big-pharma

VIVUS INC

Key Drugs

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Recent Activity

Therapeutic Areas

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

All Drugs (3)

Active (3)

Discontinued (0)

Company Info

VIVUS INC

Set Alert

Key Drugs

Top Drug Revenues ProEarly access

Revenue Over Time ProEarly access

Recent Activity

Therapeutic Areas

Pipeline Forecast

Upcoming Trial Milestones ProEarly access

Patent Cliff ProEarly access

Competitors by Therapeutic Area

All Drugs (3)

Active (3)

Discontinued (0)

Company Info